Medtronic PLC $MDT Shares Sold by Johnson Financial Group Inc.

Johnson Financial Group Inc. decreased its stake in shares of Medtronic PLC (NYSE:MDT) by 6.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 30,874 shares of the medical technology company’s stock after selling 2,040 shares during the period. Johnson Financial Group Inc.’s holdings in Medtronic were worth $2,712,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Elevation Point Wealth Partners LLC increased its stake in shares of Medtronic by 3.6% during the second quarter. Elevation Point Wealth Partners LLC now owns 15,842 shares of the medical technology company’s stock valued at $1,381,000 after acquiring an additional 551 shares during the period. Quadrant Capital Group LLC lifted its position in Medtronic by 27.4% in the second quarter. Quadrant Capital Group LLC now owns 15,185 shares of the medical technology company’s stock worth $1,324,000 after purchasing an additional 3,267 shares during the period. Vinva Investment Management Ltd boosted its stake in Medtronic by 44.0% during the 2nd quarter. Vinva Investment Management Ltd now owns 113,371 shares of the medical technology company’s stock valued at $9,752,000 after purchasing an additional 34,663 shares in the last quarter. Te Ahumairangi Investment Management Ltd increased its position in shares of Medtronic by 34.4% during the 2nd quarter. Te Ahumairangi Investment Management Ltd now owns 60,701 shares of the medical technology company’s stock valued at $5,291,000 after purchasing an additional 15,530 shares during the period. Finally, Choreo LLC raised its stake in shares of Medtronic by 10.0% in the 2nd quarter. Choreo LLC now owns 48,378 shares of the medical technology company’s stock worth $4,249,000 after buying an additional 4,413 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors.

Medtronic Price Performance

Shares of NYSE:MDT opened at $105.13 on Thursday. The company’s fifty day moving average is $95.68 and its two-hundred day moving average is $91.39. The company has a market cap of $134.85 billion, a P/E ratio of 28.96, a price-to-earnings-growth ratio of 2.42 and a beta of 0.77. Medtronic PLC has a 12-month low of $79.29 and a 12-month high of $106.33. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.31 by $0.05. The business had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.Medtronic’s revenue was up 6.6% compared to the same quarter last year. During the same quarter last year, the firm posted $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts expect that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

MDT has been the topic of several research reports. Stifel Nicolaus boosted their price target on shares of Medtronic from $90.00 to $105.00 and gave the stock a “hold” rating in a research report on Thursday, October 9th. Argus lifted their price objective on shares of Medtronic from $105.00 to $115.00 and gave the stock a “buy” rating in a research note on Tuesday, August 26th. Leerink Partners set a $120.00 target price on shares of Medtronic and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a report on Wednesday, October 8th. Finally, Royal Bank Of Canada lifted their price target on shares of Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have assigned a Hold rating to the stock. According to data from MarketBeat.com, Medtronic currently has an average rating of “Moderate Buy” and a consensus target price of $109.72.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 8,605 shares of Medtronic stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the transaction, the executive vice president owned 35,615 shares of the company’s stock, valued at $3,261,621.70. The trade was a 19.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.26% of the stock is currently owned by company insiders.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.